Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $3.80 billion. The enterprise value is $3.32 billion.
Important Dates
The next estimated earnings date is Monday, February 10, 2025, before market open.
| Earnings Date | Feb 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 146.78 million shares outstanding. The number of shares has increased by 12.00% in one year.
| Current Share Class | 146.78M |
| Shares Outstanding | 146.78M |
| Shares Change (YoY) | +12.00% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.90% |
| Owned by Institutions (%) | 54.22% |
| Float | 65.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.44 |
| P/TBV Ratio | 8.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.61, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.61 |
| Quick Ratio | 7.12 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -92.17% and return on invested capital (ROIC) is -62.80%.
| Return on Equity (ROE) | -92.17% |
| Return on Assets (ROA) | -54.54% |
| Return on Capital (ROIC) | -62.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.56M |
| Employee Count | 207 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $280,000 in taxes.
| Income Tax | 280,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.70% in the last 52 weeks. The beta is 0.63, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -37.70% |
| 50-Day Moving Average | 28.56 |
| 200-Day Moving Average | 29.09 |
| Relative Strength Index (RSI) | 38.95 |
| Average Volume (20 Days) | 952,064 |
Short Selling Information
The latest short interest is 12.67 million, so 8.63% of the outstanding shares have been sold short.
| Short Interest | 12.67M |
| Short Previous Month | 13.02M |
| Short % of Shares Out | 8.63% |
| Short % of Float | 19.29% |
| Short Ratio (days to cover) | 14.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -352.46M |
| Pretax Income | -271.89M |
| Net Income | -323.01M |
| EBITDA | -352.17M |
| EBIT | -352.46M |
| Earnings Per Share (EPS) | -$2.22 |
Full Income StatementBalance Sheet
The company has $472.94 million in cash and $47,000 in debt, giving a net cash position of $472.89 million or $3.22 per share.
| Cash & Cash Equivalents | 472.94M |
| Total Debt | 47,000 |
| Net Cash | 472.89M |
| Net Cash Per Share | $3.22 |
| Equity (Book Value) | 449.05M |
| Book Value Per Share | 3.06 |
| Working Capital | 440.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$271.64 million and capital expenditures -$659,000, giving a free cash flow of -$272.30 million.
| Operating Cash Flow | -271.64M |
| Capital Expenditures | -659,000 |
| Free Cash Flow | -272.30M |
| FCF Per Share | -$1.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |